A detailed history of Ensign Peak Advisors, Inc transactions in Sage Therapeutics, Inc. stock. As of the latest transaction made, Ensign Peak Advisors, Inc holds 42,721 shares of SAGE stock, worth $232,402. This represents 0.0% of its overall portfolio holdings.

Number of Shares
42,721
Previous 29,521 44.71%
Holding current value
$232,402
Previous $320,000 3.75%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$7.02 - $13.08 $92,664 - $172,656
13,200 Added 44.71%
42,721 $308,000
Q1 2024

May 14, 2024

SELL
$18.62 - $26.95 $27,725 - $40,128
-1,489 Reduced 4.8%
29,521 $553,000
Q4 2022

Feb 13, 2023

BUY
$32.2 - $43.61 $513,590 - $695,579
15,950 Added 105.91%
31,010 $1.18 Million
Q3 2022

Nov 14, 2022

BUY
$32.28 - $43.27 $229,833 - $308,082
7,120 Added 89.67%
15,060 $590,000
Q4 2021

Feb 11, 2022

SELL
$37.06 - $47.11 $505,016 - $641,967
-13,627 Reduced 63.18%
7,940 $338,000
Q3 2021

Nov 12, 2021

SELL
$40.26 - $57.37 $311,813 - $444,330
-7,745 Reduced 26.42%
21,567 $956,000
Q2 2021

Aug 13, 2021

BUY
$54.88 - $79.29 $480,309 - $693,946
8,752 Added 42.57%
29,312 $1.67 Million
Q1 2021

May 12, 2021

SELL
$70.65 - $96.76 $387,868 - $531,212
-5,490 Reduced 21.07%
20,560 $1.54 Million
Q3 2020

Nov 12, 2020

BUY
$41.13 - $62.45 $537,404 - $815,971
13,066 Added 100.63%
26,050 $1.59 Million
Q2 2020

Aug 12, 2020

SELL
$25.95 - $43.15 $54,884 - $91,262
-2,115 Reduced 14.01%
12,984 $539,000
Q1 2020

May 11, 2020

SELL
$26.15 - $77.24 $111,320 - $328,810
-4,257 Reduced 21.99%
15,099 $433,000
Q4 2019

Feb 14, 2020

BUY
$60.18 - $154.77 $1.16 Million - $3 Million
19,356 New
19,356 $1.4 Million

Others Institutions Holding SAGE

About Sage Therapeutics, Inc.


  • Ticker SAGE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,422,300
  • Market Cap $323M
  • Description
  • Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...
More about SAGE
Track This Portfolio

Track Ensign Peak Advisors, Inc Portfolio

Follow Ensign Peak Advisors, Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ensign Peak Advisors, Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ensign Peak Advisors, Inc with notifications on news.